Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cleviprex in Ventriculostomy Patients with ICH or SAH
NCT01042574Phase 4
Key facts
- Status
- Withdrawn
- Start
- May 2010
- Primary completion
- Dec 2010
- Countries
- 1
- Sponsor
- Methodist Healthcare System of San Antonio
- Modality
- Small Molecules
- Drugs
- clevidipine
- Conditions
- hypertension (HTN)
01
Overview
Phase 4, open-label trial of clevidipine in hypertension (HTN), sponsored by Methodist Healthcare System of San Antonio. Primary endpoint: Time to achieve the pre-specified SBP target range (110-140 mmHg) at 30 minutes. Planned start May 2010; status: withdrawn.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Endpoints
Primary
Time to achieve the pre-specified SBP target range (110-140 mmHg)
Beyond the preview
Go deeper on NCT01042574.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01042574.